Bone marrow transplantation from HL-A matched donors to patients with acute leukemia. Toxicity and antileukemic effect.
D000293:Adolescent; D000328:Adult; D001215:Asparaginase / Q000627:therapeutic use; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006087:Graft vs Host Reaction; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007945:Leukemia, Lymphoid / Q000276:immunology*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin